Corporate Profile

We are a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to address significant unmet medical needs in oncology.

Learn More

Minimum 15 minutes delayed. Source:

Latest News

I-Mab Reports Third Quarter 2024 Results

2024.11.14

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024 Estimated cash runway into 2027,

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

2024.11.06

ROCKVILLE, Md. , Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S. -based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu , PhD, MBA has been appointed

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

2024.10.31

ROCKVILLE, Md. , Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the
View All

Recent Events

View All

Investor Presentation